# KEYNOTE-021 (NCT02039674)

> A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab; pembrolizumab plus ipilimumab; pembrolizumab plus erlotinib
- Indication: locally advanced or metastatic non-small cell lung carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02039674
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Non-small Cell Lung Carcinoma
- Interventions: Pembrolizumab; Paclitaxel; Carboplatin; Bevacizumab; Pemetrexed; Ipilimumab; Erlotinib; Gefitinib
- Enrollment: 267
- Primary outcome: Part 2 Cohorts G+ and G-: Objective Response Rate (ORR)
- Primary outcome: Part 2 Cohorts D4 and H: Objective Response Rate (ORR)
- Primary outcome: All Cohorts: Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)

## Indexed commentary on KEYNOTE-021 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 6
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=keynote-021-nct02039674